

United States Patent and Trademark Office  
- Sales Receipt -

04/04/2006 CTHOMAS2 00000001 032095 09939537

01 FC:1814 130.00 DA

FEB. 7. 2006 5:13PM CLARK &amp; ELBING

NO. 223 P. 8/10

RECEIVED  
CENTRAL FAX CENTER

FEB 07 2006

PATENT  
ATTORNEY DOCKET NO. 00786/247003

Certificate of Transmission by Facsimile: Date of Transmission: <u>2/7/06</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Examiner listed below at 1-571-273-8300, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated above.	
<u>Colleen Cane</u> Printed name of person transmitting facsimile	<u>Colleen Cane</u> Signature of person transmitting facsimile

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Brian Seed et al.	Art Unit:	1648
Serial No.:	09/939,537	Examiner:	E. Le
Filed:	August 24, 2001	Customer No.:	21559
Title:	TARGETED CYTOLYSIS OF HIV-INFECTED CELLS BY CHIMERIC CD4 RECEPTOR-BEARING CELLS		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 1.321 and 3.73(b)

Pursuant to 37 C.F.R. § 1.321(b), The General Hospital Corporation, the assignee of the entire right, title, and interest in the above-captioned application, seeks to disclaim the terminal portion of the term of the patent to be granted on the application. This terminal disclaimer is binding on the grantee and its successors or assigns.

Pursuant to 37 C.F.R. § 1.321(b)(1), this terminal disclaimer is signed by an attorney of record.


Pursuant to 37 C.F.R. § 1.321(b)(2), The General Hospital Corporation hereby

Further, pursuant to 37 C.F.R. § 1.321(c)(3), this terminal disclaimer is being filed to overcome a double patenting rejection in the application. Any patent granted on the application or any resulting patent subject to reexamination proceedings shall be enforceable only for and during such period that the patent is commonly owned with the application or patent that formed the basis for the rejection.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 07 February 2006

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045